Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Solu-Medrol

(Methylprednisolone Sodium Succinate)

ApprovedSmall molecule

MMassachusetts Eye and Ear Infirmary

It's a strong anti-inflammatory steroid used to reduce swelling and suppress the immune system in serious conditions like severe allergies, autoimmune diseases, organ transplant rejection, and certain types of cancer. It works quickly when given by injection to help the body calm down its overactive inflammatory response.[2] Solu-Medrol is currently approved and in use across 38 indications[4].[1]

Solu-Medrol is one of 817 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Approved.

38

Indications

22

Total Trials

5

Active Trials

816

Competitors

Pipeline

Status by Indication[4][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Bacterial PneumoniaActive, not recruiting

Hip FractureActive, not recruiting

Type III Hypersensitivity Reaction DiseaseUnknown

StrokeActive, not recruiting

GlomerulonephritisActive, not recruiting

LymphomaUnknown

Drug-Induced Liver InjuryActive, not recruiting

Immune System DiseaseActive, not recruiting

LeukemiaUnknown

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Bacterial PneumoniaPhase 2

Active, not recruiting

Hip FractureApproved

Active, not recruiting

Type III Hypersensitivity Reaction DiseasePreclinical

Unknown

StrokePhase 3

Active, not recruiting

GlomerulonephritisPhase 3

Active, not recruiting

LymphomaPreclinical

Unknown

Drug-Induced Liver InjuryPhase 2

Active, not recruiting

Immune System DiseasePhase 1

Active, not recruiting

LeukemiaPreclinical

Unknown

Showing 10 of 36 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Proventil

Mylan Pharmaceuticals Inc

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Conventional

PPopulation Health Research Institute

Moderna COVID-19 Vaccine

Pfizer-COVID-19 Vaccine

Other Tkis

Opaganib

RRedHill Biopharma Limited

Saliva Collection

DDirection Centrale du Service de Santé des Armées

C21

VVicore Pharma AB

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Headaches Associated With Subarachnoid Hemorrhage (SAH)

NCT07054801

Q3 2027

Phase 3Recruiting

Stroke

NCT07202143

Q4 2027

Phase 2Not yet recruiting

Acute Graft Versus Host Disease

NCT07185633

Q4 2029

N/ANot yet recruiting

Ischemic Stroke

NCT07175649

Clinical

Trials by Indication[1]

Acute Graft Versus Host Disease2 trials

Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract

Withdrawn·WWake Forest University Health Sciences·Phase 2·NCT02425813

Study of Gecacitinib-corticosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host Disease

Not yet recruiting·BBin Gu·Phase 2·NCT07185633·25 enrolled

Stroke2 trials

Methylprednisolone for Stroke With Large Infarct Core and Post-stroke Lymphocytopenia

Recruiting·YYiLin·Phase 3·NCT07202143·200 enrolled

Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke

Active, not recruiting·WWan-Jin Chen·Phase 3·NCT06360458·928 enrolled

Hip Fracture1 trial

Preoperative Single Glucocorticoid Hip Fracture Hip Fracture Surgery

Completed·HHvidovre University Hospital·Phase 4·NCT02317601·122 enrolled

Total Knee Replacement1 trial

Pre-operative Intravenous Steroid in Total Knee Replacement for Pain Relief and Recovery

Completed·QQueen Elizabeth Hospital, Hong Kong·Phase 4·NCT03082092·60 enrolled

Headache1 trial

Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1

Completed·TThe Cooper Health System·Phase 1·NCT06462781·10 enrolled

15 more indications

Ischemic stroke1 trial

Methylprednisolone Sodium Succinate With Endovascular ThRombectomy for Large Ischemic STroke

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·N/A·NCT07175649·912 enrolled

Injury1 trial

Corticosteroids and Myocardial Injury in CAP (COLOSSEUM TRIAL)

Unknown status·UUniversity of Roma La Sapienza·Phase 3·NCT03745664·122 enrolled

Pneumonia1 trial

Sphingosine-1-phosphate and Pneumonia

Unknown status·TTaipei Medical University WanFang Hospital·Phase 2/3·NCT04007328·400 enrolled

Graft Versus Host Disease1 trial

Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease

Completed·MMassachusetts Eye and Ear Infirmary·Phase 1·NCT01977781·40 enrolled

Acute Lymphoblastic Leukemia1 trial

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Completed·OOHSU Knight Cancer Institute·Phase 1·NCT02779283·7 enrolled

Severe Acute Respiratory Syndrome1 trial

Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19

Completed·FFundação de Medicina Tropical Dr. Heitor Vieira Dourado·Phase 2·NCT04343729·416 enrolled

Conditioning1 trial

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

Terminated·SStanford University·Phase 3·NCT00568633·58 enrolled

Deafness1 trial

Sudden Deafness Treatment Trial

Completed·MMassachusetts Eye and Ear Infirmary·Phase 3·NCT00097448·255 enrolled

COVID-191 trial

Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19

Terminated·HHospital Sao Domingos·Phase 2·NCT04377503·30 enrolled

Asthma1 trial

Oral Glucocorticosteroid in the Treatment of Severe Asthma Exacerbation in Hospitalized Patients

Completed·HHamamatsu University·Phase 4·NCT00627731·50 enrolled

Glucocorticoids1 trial

Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02798523·33 enrolled

Epilepsy1 trial

Pilot Trial to Evaluate The Effect of Oral Methylprednisolone on Seizure Frequency in Children With Epilepsy

Unknown status·LLouisiana State University Health Sciences Center in New Orleans·Phase 1/2·NCT04219995·10 enrolled

Alopecia Areata1 trial

Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata

Completed·KKing Saud University·Phase 4·NCT01167946·42 enrolled

Acute Respiratory Distress Syndrome1 trial

Early Low Dose Steroid Therapy of Acute Respiratory Distress Syndrome

Completed·NNational Cancer Center, Korea·Phase 2·NCT00290602·40 enrolled

Headaches Associated With Subarachnoid Hemorrhage (SAH)1 trial

Intra-arterial Lidocaine and Methylprednisolone Injection Into the Middle Meningeal Artery For Treatment of Headache Associated With Subarachnoid Hemorrhage

Recruiting·DDaniel Raper, MBBS·Phase 2·NCT07054801·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for Methylprednisolone Sodium Succinate. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Solu-Medrol drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Methylprednisolone Sodium Succinate compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Methylprednisolone Sodium Succinate. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Massachusetts Eye and Ear Infirmary company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Glucocorticoid Receptor Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: MMassachusetts Eye and Ear Infirmary

Related News